Lupin’s subsidiary - Lupin Pharmaceuticals Inc.has received final approval for its Pirmella 7/7/7 (Norethindrone and Ethinyl Estradiol Tablets USP, 0.5mg/ 0.035mg, 0.75mg/ 0.035mg and 1mg/0.035mg) and Pirmella 1/35 tablets (Norethindrone and Ethinyl Estradiol Tablets USP1mg/0.035mg) from the United States Food and Drugs Administration (US FDA) to market a generic version of Janssen Pharmaceuticals, Inc’s Ortho-Novum 7/7/7 tablets and Ortho-Novum 1/35 tablets..
Lupin’s Pirmella 7/7/7 and Pirmella 1/35 tablets is indicated for the prevention of pregnancy in women who elect to use the product as a method of contraception. The total sales for both Ortho-Novum 7/7/7 tablets and Ortho-Novum 1/35 oral contraception tablets stood at $96.50 million.
Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 2000.75 |
| Dr. Reddys Labs. | 1144.35 |
| Cipla | 1466.00 |
| Lupin | 2419.10 |
| Zydus Lifesciences | 1115.50 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: